|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.4000 - 1.4000|
|52 Week Range||1.3300 - 1.4700|
|Beta (5Y Monthly)||1.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PARIS & BOSTON, April 21, 2022--Regulatory News: Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY), inventor of Cellvizio®, the multidisciplinary probe and needle confocal laser endomicroscopy (p/nCLE) platform, today announced financial results (unaudited) for the year ended December 31, 2021, and its sales for the first quarter ended March 31, 20221.
Dose increase of R327 Dose increase of R327 Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee affirms ‘low-dose’ cohort clinical trial complete, endpoints achieved – recommends ‘high dose’ cohort dosing to beginCommittee clears cohort five (R327 – 2,000mg IV) dosing – subjects recruited and dosing underway SYDNEY, Australia, April 13, 2022 (GLOBE NEWSWIRE)
PARIS & BOSTON, April 12, 2022--Regulatory News: Mauna Kea Technologies (Euronext: MKEA, ‘Mauna Kea’) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform today announced a new U.S. FDA 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a molecular imaging agent, the first of its kind, for real-time in vivo visualization during endoscopic, laparoscopic, and needle-based procedures.